Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$1.08 USD
-0.04 (-3.57%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.08 0.00 (0.00%) 7:02 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Protalix BioTherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 65 | 48 | 38 | 63 | 55 |
Cost Of Goods | 23 | 20 | 16 | 11 | 11 |
Gross Profit | 43 | 28 | 22 | 52 | 44 |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 41 | 42 | 49 | 55 |
Income After Depreciation & Amortization | 10 | -13 | -20 | 3 | -11 |
Non-Operating Income | -2 | -1 | -7 | -9 | -8 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 9 | -14 | -28 | -7 | -18 |
Income Taxes | 0 | 1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 8 | -15 | -28 | -7 | -18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 8 | -15 | -28 | -7 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 12 | -12 | -17 | 7 | -6 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 4 | 5 | 5 |
Income After Depreciation & Amortization | 10 | -13 | -20 | 3 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 82.42 | 48.47 | 44.14 | 29.15 | 14.84 |
Diluted EPS Before Non-Recurring Items | 0.09 | -0.31 | -0.62 | -0.22 | -1.23 |
Diluted Net EPS (GAAP) | 0.09 | -0.31 | -0.62 | -0.22 | -1.23 |
Fiscal Year end for Protalix BioTherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 13.47 | 3.75 | 10.49 | 10.35 | 35.08 |
Cost Of Goods | 9.46 | 2.60 | 8.86 | 4.89 | 6.15 |
Gross Profit | 4.02 | 1.15 | 1.63 | 5.45 | 28.93 |
SG&A, R&D, and Dept/Amort Expenses | 6.44 | 6.01 | 7.24 | 7.34 | 8.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.42 | -4.86 | -5.61 | -1.89 | 20.42 |
Non-Operating Income | 0.16 | 0.12 | -0.81 | 0.17 | -0.77 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.27 | -4.73 | -6.43 | -1.72 | 19.65 |
Income Taxes | -0.07 | -0.14 | -0.38 | 0.13 | 0.31 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.20 | -4.60 | -6.04 | -1.85 | 19.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.20 | -4.60 | -6.04 | -1.85 | 19.34 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 73.31 | 73.04 | 82.42 | 83.78 | 83.20 |
Diluted EPS Before Non-Recurring Items | -0.03 | -0.06 | -0.07 | -0.04 | 0.21 |
Diluted Net EPS (GAAP) | -0.03 | -0.06 | -0.03 | -0.04 | 0.21 |